€ million |
|
Note |
|
2022 |
|
2021 |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales |
|
|
22,232 |
|
19,687 |
|||||||
Cost of sales |
|
|
-8,527 |
|
-7,351 |
|||||||
Gross profit |
|
|
|
13,705 |
|
12,335 |
||||||
|
|
|
|
|
|
|
||||||
Marketing and selling expenses |
|
|
-4,714 |
|
-4,304 |
|||||||
Administration expenses1 |
|
|
|
-1,306 |
|
-1,227 |
||||||
Research and development costs1 |
|
|
-2,521 |
|
-2,426 |
|||||||
Impairment losses and reversals of impairment losses on financial assets (net) |
|
|
-6 |
|
1 |
|||||||
Other operating income |
|
|
486 |
|
528 |
|||||||
Other operating expenses1 |
|
|
-1,170 |
|
-730 |
|||||||
Operating result (EBIT)2 |
|
|
|
4,474 |
|
4,179 |
||||||
|
|
|
|
|
|
|
||||||
Finance income |
|
|
90 |
|
62 |
|||||||
Finance costs |
|
|
-277 |
|
-317 |
|||||||
Profit before income tax |
|
|
|
4,287 |
|
3,924 |
||||||
|
|
|
|
|
|
|
||||||
Income tax |
|
|
-948 |
|
-859 |
|||||||
Profit after tax |
|
|
|
3,339 |
|
3,065 |
||||||
thereof: attributable to shareholders of Merck KGaA, Darmstadt, Germany (net income) |
|
|
|
3,326 |
|
3,055 |
||||||
thereof: attributable to non-controlling interests |
|
|
14 |
|
10 |
|||||||
|
|
|
|
|
|
|
||||||
Earnings per share (in €) |
|
|
|
|
|
|||||||
Basic |
|
|
|
7.65 |
|
7.03 |
||||||
Diluted |
|
|
|
7.65 |
|
7.03 |
||||||
|
||||||||||||